



Biolight Life Sciences Ltd. ("the Company")

September 8, 2025

To: Israel Securities Authority www.isa.gov.il

To: Tel-Aviv Stock Exchange Ltd. www.tase.co.il

Re: Biolight Life Sciences - Dividend Distribution Policy

The Company is pleased to announce that on September 7, 2025, the Company's Board of Directors approved a dividend distribution policy. According to this policy, the Company will aim to distribute a dividend to its shareholders amounting to 50% of the "**Net Cash Amount**" received by the Company from the realization of its holdings in its portfolio companies. This amount will be calculated after deducting the investment cost in the portfolio company and reducing any taxes and expenses incurred in connection with the investment and the realization of the holding in the portfolio company.

The distribution and amount of any dividend will be subject to a specific decision by the Company's Board of Directors, which will consider a dividend distribution following the completion of a transaction for the realization of holdings in a portfolio company as described above. All distributions are subject to applicable law, including the distribution tests stipulated in the Companies Law, 1999, any restrictions under existing agreements (if any), and the Company's financial condition and cash flow needs, taking into account, among other things, its liabilities and business plan.

It should be clarified that the dividend distribution policy does not limit the discretion of the Company's Board of Directors when considering a potential dividend distribution, nor does it constitute a commitment to the Company's security holders to distribute a dividend. The Board of Directors has full authority to decide whether or not to distribute a dividend, and if so, when and in what amount, all at the Board's discretion from time to time.

Sincerely,

Biolight Life Sciences Ltd.

NON-BINDING TRANSLATION

The above-mentioned immediate report is a free translation of the Company's immediate report in Hebrew published on the TASE on September 8, 2025. In the event of inconsistency between this version and the Hebrew one, the Hebrew language version shall prevail.